Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Jiafen Gong[1], Gengming He[1,2], Cheng Wang[1], Claire Bartlett[3] , Naim Panjwani[1], Scott Mastromatteo[1], Fan Lin[1], Katherine Keenan[1,3], Julie Avolio[3], Anat Halevy[1], Michelle Shaw[3], Mohsen Esmaeili[1] , Guillaume Côté-Maurais[4], Damien Adam[4,5], Stéphanie Bégin[4], Candice Bjornson[6], Mark Chilvers[7], Joe Reisman[8], April Price[9], Michael Parkins[10], Richard Van Wylick[11], Yves Berthiaume [5], Lara Bilodeau[12], Dimas Mateos-Corral[13], Daniel Hughes[13], Mary J. Smith[14], Nancy Morrison[15], Janna Brusky[16], Elizabeth Tullis[17], Anne L. Stephenson[17], Bradley S. Quon[18], Pearce Wilcox[18], Winnie M. Leung[19], Melinda Solomon[20], Lei Sun [2,21], Emmanuelle Brochiero[4,5], Theo J. Moraes[3,20], Tanja Gonska[3,22], Felix Ratjen[3,23], Johanna M. Rommens[1,24], Lisa J. Strug[1,2,21,25, 26,*]

Affiliations:

[1]Program in Genetics and Genome Biology, The Hospital for Sick Children; Toronto, ON, Canada.

[2]Biostatistics Division, Dalla Lana School of Public Health, University of Toronto; Toronto, ON, Canada.

[3]Program in Translational Medicine, The Hospital for Sick Children; Toronto, ON, Canada.

[4]Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.

[5]Department of Medicine, Faculty of Medicine, Université de Montréal; Montréal, QC, Canada.

[6]Alberta Children's Hospital; Calgary, AB, Canada.

[7] British Columbia Children's Hospital; Vancouver, BC, Canada.

[8] The Children's Hospital of Eastern Ontario; Ottawa, ON, Canada.

[9] The Children's Hospital, London Health Science Centre; London, ON, Canada.

[10] Foothills Medical Centre; Calgary, AB, Canada.

[11] Kingston Health Sciences Centre; Kingston, ON, Canada.

[12] Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec-

Université Laval; Québec City, QC, Canada.

[13] IWK Health Centre; Halifax, NS, Canada.

[14] Faculty of Medicine, Memorial University of Newfoundland; St. John's, NL, Canada.

[15] Queen Elizabeth II Health Sciences Centre; Halifax, NS, Canada.

[16] Jim Pattison Children's Hospital; Saskatoon, SK, Canada.

[17] St. Michael's Hospital; Toronto, ON, Canada.

[18] St. Paul's Hospital; Vancouver, BC, Canada.

[19] University of Alberta Hospital; Edmonton, AB, Canada.

[20] Respiratory Medicine, Hospital for Sick Children; Toronto, ON, Canada.

[21] Department of Statistical Sciences, University of Toronto; Toronto, ON, Canada.

[22] Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children;

Toronto, ON, Canada.

[23] Department of Paediatrics, University of Toronto; Toronto, ON, Canada.

[24]Department of Molecular Genetics, University of Toronto; Toronto, ON, Canada.

[25]The Centre for Applied Genomics, Hospital for Sick Children; Toronto, ON, Canada.

[26]Department of Computer Science, University of Toronto; Toronto, ON, Canada.

[*]Corresponding author: Lisa J. Strug, PhD

Program in Genetics and Genome Biology

SickKids Research Institute

Room 12.9705, PGCRL

686 Bay Street

Toronto, ON

M5G 0A4

Email: lisa.strug@utoronto.ca

Tel: +1416-813-7654 X301762

Abstract

Background: Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator (*CFTR*) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs. Alternative epithelial ion channel/transporters such as SLC26A9 could compensate for CFTR dysfunction, providing therapeutic targets that may benefit all individuals with CF.

Method: We investigate the relationship between rs7512462, a marker of *SLC26A9* activity, and lung function pre- and post-treatment with CFTR modulators in Canadian and US CF cohorts, in the general population, and in those with chronic obstructive pulmonary disease (COPD).

Results: Rs7512462 CC genotype is associated with greater lung function in CF individuals with minimal function variants (for which there are currently no approved therapies; p=0.008); and for gating (p=0.033) and p.Phe508del/ p.Phe508del (p=0.006) genotypes upon treatment with CFTR modulators. In parallel, human nasal epithelia with CC and p.Phe508del/p.Phe508del after Ussing chamber analysis of a combination of approved and experimental modulator treatments show greater CFTR function (p=0.0022). Beyond CF, rs7512462 is associated with lung function in a meta-analysis of the UK Biobank and Spirometa Consortium (min p=2.74×10^{-44}) and provides p=0.0891 in an analysis of COPD case-control status in the UK Biobank defined by spirometry.

Conclusion: These findings support SLC26A9 as a therapeutic target to improve lung function for all people with CF and in individuals with other obstructive lung diseases.

Key words: SLC26A9, Cystic Fibrosis, CFTR modulator treatment, precision medicine, COPD

Background

Cystic Fibrosis [CF (MIM:219700)] is a common life-limiting autosomal recessive genetic

disease caused by pathogenic variants in the cystic fibrosis transmembrane conductance

regulator (CFTR; MIM:602421). CF affects multiple organs; morbidity in the pancreas and

intestine are seen at birth (1-3), while progressive lung disease is experienced throughout the

course of disease and is the major cause of morbidity and mortality. Variability in disease

severity across the affected organs is due, in part, to variation in other genes, referred to as

modifier genes. Modifier genes impact phenotypic expressivity in the presence of a

dysfunctional major causal gene, for example, *CFTR* (1, 4-7).

CFTR is localized to the cell membrane of epithelial cells and functions as an ion channel. Over

400 variants have been reported to cause CF through variable effects on protein function

(http://cftr2.org; (8)). CF-causing mutations impact apical chloride and bicarbonate transport,

altering hydration and pH of airway surface liquid resulting in viscous mucus. Accumulation of

this viscous mucus leads to cycles of infection and inflammation, obstructing and damaging the

airways, resulting in progressive lung damage and end-stage lung disease (9).

Developments in CF therapeutics over the past decade have been transformative, altering the

management paradigm from treating the downstream consequences of dysfunctional CFTR and

delaying the progression of the disease, to treating the basic defect in an individual's CFTR

itself: *precision medicine*. New drugs enhance CFTR function by directly targeting the different

defects in the protein. For example, individuals with gating mutations have access to a highly

effective modulator, ivacaftor (IVA), which is a potentiator that increases the opening probability

of CFTR to aid chloride and bicarbonate ion transport in CF epithelia (10). The most common

CF causing allele Phe508del (c.1521_1523delCTT; p.Phe508del) (11) displays minimal CFTR

at the apical membrane due to processing defects (5, 6), and once at the cell surface the

Phe508del protein exhibits reduced opening probability and stability. Pharmaceuticals targeting

this defect include a combination therapy of IVA and a CFTR corrector lumacaftor (LUM) or

tezacaftor (TEZ) that improves the Phe508del processing to increase cell surface localized

protein as well as channel gating. More recently, a triple combination therapy of another

corrector, elexacaftor, combined with tezacaftor and ivacaftor (ETI) has been approved in the

United States (US) for individuals with at least one Phe508del aged 6 and above or other

mutations responsive to Trikafta (https://www.cff.org/Trials/Pipeline/details/10150/Elexacaftor-

tezacaftor-ivacaftor-Trikafta). Elexacaftor stabilizes the protein within the cell membrane,

resulting in greater improvements in lung function over LUM/IVA or TEZ/IVA alone (12, 13).

ETI is now indicated by the FDA for 90% of individuals with CF (https://www.fda.gov/news-

events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis).

Although significant progress has been made in the development of pharmaceuticals for

precision medicine in CF, several challenges remain. First, not all individuals with *CFTR*

genotypes for which eligible pharmaceuticals are available respond to those treatments. Second,

for those who do show a positive improvement in lung function, there is significant variability in

the response (12-15), which could be augmented with additional therapies. Third, there are loss

of function alleles that cannot be addressed using the current paradigm, and therefore an

alternative approach to therapy beyond potentiators and correctors of CFTR is necessary.

Several alternative approaches are being actively pursued, including CFTR gene restoration

and/or correction or alternative targets (9). Conceptually, alternative targets to CFTR aim to

compensate for the abnormal dehydrated airway surface liquid that results from dysfunctional

CFTR by modulating other ion channels, transporters and pumps (16-20) providing therapeutic

options for those individuals with genotypes that do not produce CFTR protein and could

assuage limited responses to existing CFTR modulators.

The clinical success rate of drugs in development is appreciably higher when there is human

genetic evidence that supports a drug target (21). Genome-wide modifier gene studies in CF have

aimed to identify genetic loci that impact disease severity in the presence of CFTR dysfunction

in a hypothesis-free approach. First identified in a genome-wide association study (GWAS) of

intestinal obstruction in CF (7), the C allele of rs7512462 in intron 5 of Solute Carrier Family 26

member 9 (*SLC26A9*) (chr1:205899595, hg19) has consistently demonstrated a beneficial effect

for several CF co-morbidities, including in the exocrine (2, 3) and endocrine pancreas (4, 22).

These co-morbidities appear to originate from pre-natal dysfunction in the CF pancreas (1, 3,

23). According to the Genotype Tissue Expression project (GTEx; (24) and

http://www.gtexportal.org/home/), rs7512462 is an expression quantitative locus (eQTL) for

SLC26A9 where the C allele is associated with greater expression in the adult pancreas

(p=1.2×10^{-5}, effect size=0.27). Rs7512462 and additional *SLC26A9* eQTLs in the region of chr1:

205,806,897- 206,006,897(hg19) colocalize with the CF co-morbidity (meconium ileus) GWAS

summary statistics (1), supporting gene expression variation is responsible for the observed CF

GWAS finding.

Given the importance of attenuating progressive lung disease in CF, there was significant interest

in investigating the contribution of *SLC26A9* to lung function despite a lack of association

evidence with rs7512462 across a broad CF population, including the largest CF GWAS of lung

function to date (5). SLC26A9 is an anion chloride channel/transporter in epithelial cells that

contributes to constitutive apical chloride conductance and enhances cAMP-regulated CFTR

currents (25-28) and *Slc26a9$^{-/-}$/Cftr$^{-/-}$* mice show worse post weaning survival over *Cftr$^{-/-}$* models

(29). Rs7512462 appears to associate with both the residual and activated current in lung cells

(30, 31). In individuals with *CFTR* variants that maintain apical membrane localization,

rs7512462 showed evidence of association with CF lung function (31) and the relationship was

greatly enhanced upon treatment with the CFTR modulator IVA where the C allele was

associated with greater lung function improvement (31, 32). That rs7512462 was not shown to

be a strong modifier of CF lung disease (5, 31) in the absence of treatment with CFTR correctors

but is associated with lung function in a non-CF population study (9, 33) is consistent with

functional studies, where differential SLC26A9 interaction with wild-type CFTR and with

Phe508del-CFTR in human bronchial epithelia (HBE) has been reported (25, 31).

The functional and CF population studies highlight the potential of SLC26A9 as a target to

improve CF outcomes across the affected organs and to improve response to approved CFTR

modulators. However, several questions remain including whether population studies support

SLC26A9 as providing alternative chloride transport in individuals with genotypes for which

there are no approved therapies; whether enhancing SLC26A9 will improve lung function

response to CFTR modulators targeting the most common Phe508del variant; which patient-

specific cell-based models of the airway demonstrate SLC26A9 expression; and whether

enhancing SLC26A9 could benefit other obstructive lung diseases such as chronic obstructive

pulmonary disease (COPD) in light of the rs7512462 association with lung function in non-CF

population studies (33).

Through continued recruitment into the Canadian CF Gene Modifier Study (CGMS) and in

collaboration with the US PROSPECT observational study ((34);

https://clinicaltrials.gov/ct2/show/NCT02477319), we investigate the association between

rs7512462 and (1) lung function in individuals with CF with different *CFTR* genotypes including

variants that result in no CFTR protein product (i.e. minimal function alleles); (2) individual lung

function responses to CFTR modulators IVA and LUM/IVA; (3) CFTR function in primary

cultured human nasal epithelia (HNE) from individuals with CF in response to approved and

experimental CFTR modulators; and (4) other phenotypes in non-CF populations to inform the

clinical utility of SLC26A9 modulators beyond applications in CF.

Methods

Study Design

The Canadian Cystic Fibrosis Gene Modifier Study (CGMS) is a registry-based observational

genetics study. The US Part B Cystic Fibrosis Foundation (CFF) Therapeutics PROSPECT

study is an observational study of modulator treatment. The current study investigates the

relationship between rs7512462 and lung function pre- and post-CFTR modulators in Canadian

and US CF cohorts; in the general population; and in a case control study of chronic obstructive

pulmonary disease (COPD).

Clinical data collected as part of the CGMS include forced expiratory volume in 1 second

(FEV$_1$), age, sex, and height which are all obtained from the Canadian CF Patient Data Registry

(CCFRD), with occasional augmentation by chart review at the participating sites. Genetic data

is linked to clinical data through an approved data access agreement with Cystic Fibrosis

Canada. Part B of the CFF Therapeutics PROSPECT observational study

(https://clinicaltrials.gov/ct2/show/NCT02477319 and (34)) in the US evaluated the effectiveness

of LUM/IVA and collected buffy coat and clinical data from individuals with two copies of the

Phe508del variant who were prescribed LUM/IVA. We received the PROSPECT study buffy

coat and corresponding clinical data from the US CFF. DNA was extracted for genotyping on

Illumina platforms as described in Supplementary Information for sample genotyping and quality

control.

Phenotypes, Sampling and Inclusion Criteria

The CGMS has enrolled 3,257 participants from 9 provinces and 35 clinics across Canada with a

range of *CFTR* genotypes that are reflective of the Canadian CF population. To investigate the

association of *rs7512462* with pre-treatment lung function, we specifically study the subgroups

of the CGMS who are: (1) homozygous for Phe508del; (2) carrying at least one copy of the

G551D (c.1652G>A;p.Gly551Asp) variant or another gating variant approved for IVA; and (3)

individuals with two *in trans* minimal function (MF) variants (https://www.cff.org/research-

clinical-trials/types-cftr-mutations) for which there are no CFTR modulators approved; these

include nonsense, splicing and small indel variants that cannot be targeted by CFTR modulators

(Fig. 1). Lung function severity in the absence of modulator treatment for participants in CGMS

was measured by Saknorm, the survival adjusted average CF-specific Kulich FEV_1 percentiles

that is normalized (5, 31, 35). For participants whose recruitment year was after 2008, Saknorm

is calculated using Canadian CF-specific reference equations from 2008–2014 (36), rather than

US reference equations (37). Saknorm enables comparison of CF lung disease across the age

spectrum where there is differential mortality and is therefore used as a phenotype in CF genetic

association studies. After quality control (QC), n=89 participants with at least one gating

mutation, n=1,266 with homozygosity for Phe508del and n=63 with two MF alleles in trans are

included in the analysis. Of these participants, 54 individuals with at least one gating mutation

and 1,013 who are homozygous for Phe508del were also included in a previous publication (31)

(Fig. 1).

CGMS participants prescribed IVA or LUM/IVA were also included in the treatment response

study, together with the US PROSPECT participants for LUM/IVA (Fig. 1, Table 1).

Participants from the PROSPECT study were younger and healthier than the Canadian cohort (as

measured by forced expiratory volume in one second (FEV_1) percent predicted (FEV_{1pp})) at

treatment initiation (Table 1). Similar to (31), all participants included for modulator lung

response analysis had a baseline measurement between 30 and 96 FEV_{1pp} measured within 3

months prior to, or on, the treatment initiation date. The CGMS data is obtained from the

CCFRD with variable longitudinal entry depending on the resources of the individual clinics

across the country while PROSPECT collected regular measurements at 1, 3, 6 and 12 months

after treatment initiation. To account for this difference, the LUM/IVA treatment response is

defined as the difference in FEV_{1pp} between the first visit on treatment within 5-7 months and

that measured at baseline following convention in the literature (38); for the IVA study, aligned

with reported treatment responses seen by 15 days (10), the difference between mean FEV_{1pp}

within 15 to 400 days to FEV_{1pp} baseline (31), as well as the difference between the longitudinal

FEV_{1pp} within 15 to 400 days to FEV_{1pp} baseline are used. We also investigated an IVA analysis

with treatment response defined as the difference from the 1st FEV_{1pp} within 15 to 60 days after

the treatment initiation; the conclusion is comparable but because the sample size is reduced to

33, we report the mean treatment response and longitudinal treatment response in 15 to 400 days.

After phenotype and genotype QC, 91 participants from PROSPECT and 104 CGMS

participants were included in the genetic analysis for LUM/IVA and 45 for the IVA study (see

Supplementary Table 1 for sample exclusion; Fig. 1).

We also investigated CFTR function in 46 CF Canada SickKids Program in CF Individualized

Therapy (CFIT; (39)) participants homozygous for Phe508del whose nasal epithelia were

brushed, cultured to passage 2 (P2) and mounted in a circulating Ussing chamber. Thirty-six

individuals who underwent brushing prior to modulator initiation and for whom we had

rs7512462 genotype are included in the Ussing chamber analysis (Supplementary Information

for additional cell culture and Ussing chamber study information; Fig. 1).

A subset of the CGMS cohort (n=82; Fig. 1) and 6 healthy controls had RNA from their nasal

cells sequenced as part of CFIT. In addition, we have sequenced nasal cells for 9 CFIT samples

cultured to passage 3 (P3) at two time points (14-16 days and 26-30 days). We also sequenced

the RNA from de-identified CF individuals who underwent lung transplantation, obtained from

paired human bronchial and nasal epithelia; n=17 independent pairs of uncultured primary HNE

and HBE and n=16 cultured HNE and HBE pairs (Supplementary Information for sampling and

cell culturing).

Illumina Smart-Seq2 single-cell RNA data from three individuals were obtained from the Human

Lung Cell Atlas (40). The donors consisted of two males and one female, aged between 46 to 75

years. The samples were freshly resected lung tissues obtained during surgery with confirmed

normal histology (except for very mild emphysema in some of the samples from one individual).

Summary association statistics from other GWAS phenotypes were obtained from the GWAS

ATLAS (41) (Supplementary Information for PheWAS data extraction). Association between

rs7512462 and lung function was assessed using the UK Biobank data under application #40946,

or was investigated using summary statistics from (33) when available.

Association Analysis of rs7512462

i.   Association with lung function (Saknorm) by CFTR genotype group

To assess whether rs7512462 was associated with Saknorm in the different *CFTR* genotype

groups, we carried out a stratified analysis, separately for those with gating variants (or the

subset specifically with G551D), those homozygous for Phe508del and those with two minimal

function (MF) variants, using both additive and recessive models. In each CFTR genotype

subgroup, the association analysis used the R package 'rms' (42) to obtain a robust variance

estimator and the linear regression included an indicator for which reference cohort was used to

calculate the Saknorm phenotype. For individuals with at least one G551D variant, the

rs7512462 association in CGMS is meta-combined with that from four previously published

cohorts: a cohort from France (32) and 3 from the United States (43). For CF individuals

homozygous for Phe508del or for those with at least one gating mutation, the rs7512462

association results are also meta-combined with those reported in (32). Meta-analysis is

implemented using inverse variance and sample size weighting with the R functions 'metagen' in

the package 'meta' (44) and 'rma' in the package 'metafor' (45), respectively and the R package

'forestplot' is used to generate forest plots (46). To assess whether lung function is different

between the three *CFTR* genotype groups, we regressed Saknorm on two indicators for the three

CFTR genotype categories. Additionally, to assess whether the effects of rs7512462 genotype on

Saknorm were different between the three *CFTR* genotype groups, we included an SNP-*CFTR*

interaction term in the regression model and performed an F-test using the aov function. All

analyses adjusted for the reference cohort used to calculate Saknorm and only two-sided p-values

less than 0.05, and with the direction that the C alleles is beneficial, are considered significant.

ii.   Association with response to modulator treatment

We also use multivariable regression with robust variance estimation to assess the association of

rs7512462 with the modulator FEV_{1pp} response, where rs7512462 is coded recessively to align

with what is observed in exploratory data analysis (Fig. 2). For the association with treatment

response to IVA, covariates include age and FEV_{1pp} at baseline. To account for the variable

follow-up days and the variable baseline measure time prior to the treatment initiation, we also

implement a linear mixed-effect model for participants on IVA and with follow-up

measurements between 15 to 400 days using the R function 'lmer' in the package 'lme4' with a

random intercept (47).

For treatment response to LUM/IVA, besides rs7512462, age and FEV_{1pp} at baseline, principal

components (PCs) were also included to adjust for population structure, which were calculated

from the PROSPECT or the combined CGMS and PROSPECT studies by the R function PC-

AiR in the GENESIS package (48, 49) using the kinship matrix estimated by KING 2.2.4 (50).

The significant PCs were selected based on the Tracy-Widom test using the function twtable in

POPGEN of Eigensoft (51) ; 7 PCs were included for the US PROSPECT analysis and 4 PCs for

the US PROSPECT+CGMS combined analysis. Analysis of the Ussing chamber data to assess

association of CFTR functional response to CFTR modulators with rs7512462 uses multivariable

regression with a robust variance estimator, adjusted for a binary indicator of culture media. The

boxplots are obtained using the functions ggplot and geom_boxplot from the package ggplot2 in

R (52) and the function geom_jitter from ggplot2 is used to overlay the individual measurements

in a stripchart.

iii.   Association analysis with COPD and non-CF lung function in the UK Biobank and

SpiroMeta Consortium

Genetic association analyses for spirometry measures in the UK Biobank were conducted using

imputed (v3) phenotypic data obtained from the UK Biobank (53, 54). In-house scripts, R

package rbgen and C++ tool bgenix (55), were used to index, subset and perform association

analysis using imputed dosage (53). COPD was defined according to the GOLD (levels 2 to 4)

criteria of moderate to very severe airflow limitation (56) (FEV_1/FVC ratio < 0.7 and FEV_{1pp} <

80%). Prior to analysis, spirometry and genotyping quality control (QC) were carried out as

suggested in (33), with the exception of kinship and ethnicity analyses, where we opted to use

KING's (v.2.0) --unrelated option (50) and the UKBB's UID 22006 for the identification of

Europeans. This QC method is more conservative and yielded 263,461 participants compared to

321,047 participants in (33). We removed individuals with incomplete data for sex

(UID=22001), age (UID=21022), height (UID=50), and smoking status (ever/never,

UID=20160). FEV_{1pp} was calculated using the Global Lungs Initiative (GLI) calculator using the

best FEV_1, age (UID=21022), height (UID=50), and sex (UID=22001). From these, 22,071

participants fit the spirometrically-defined COPD criteria. Summary statistics for population-

level GWAS of spirometry (FEV_1/FVC ratio, and peak expiratory flow (PEF)) were obtained

from meta-analysis of the UKBB and SpiroMeta Consortium (33). Phenotypic analysis at the

SLC26A9 locus included the best measures for PEF, FEV_{1pp} and FEV_1/FVC ratio. The best

measure for FEV_1 (UID=20150) and FVC (UID=20151) were defined as the highest measure

from the array of values of up to three blows (UID=3063 and 3062, respectively) that were

deemed acceptable according to blow quality metrics (UID=20031): "blank", "ACCEPT",

"BELOW6SEC ACCEPT" and "BELOW6SEC"; and a back-extrapolated volume (derived from

the blow curve time series, UID=3066) greater than 5% or less than 150mL, as explained in (33).

The best FEV_1/FVC is calculated from the selected best FEV_1 and FVC after determining blow

reproducibility within 250mL from any other blow as explained in (33). Principal components

were calculated using flashPCA2 v2.1 (57) which is designed for Biobank-scale data. All

association models included three principal components, sex, age, age^2, sex $\times$ age, sex $\times$ age^2 and

smoking (ever/never). All spirometry measures were inverse rank normal transformed prior to

association analysis using the RNOmni R package's (v0.7.1) rankNorm function (58).

Association summary statistics from each of the lung function phenotypes were then used for

colocalization analysis in LocusFocus (v1.4.9; (59)).

Haplotype analysis of CGMS in CF participants homozygous for Phe508del

Risk haplotypes that include rs7512462 were reported to associate with age-of-onset of CF-

related diabetes in individuals homozygous for Phe508del (60) and here we similarly construct

these haplotypes and assess their association with Saknorm. Lam et al (60) constructed the

haplotypes from 41 common SNPs (MAF>15%) in the same linkage disequilibrium (LD) block

as rs7512462 and found that two common haplotypes are associated with later CFRD onset (low

risk (LR), minor haplotype frequency [MHF]=28.4%, p=1.14×10^{-3}) and earlier CFRD onset

(high risk (HR), MHF=24.1%, p=4.34×10^{-3}) (n=594) when using PLINK's haplotype analysis

command (--chap and --each-vs-others).

To mimic this haplotype analysis we used imputed genotype data from the CGMS (1) in

individuals homozygous for Phe508del (n=1,266). The imputed data included 40 of the 41

variants used by Lam et al (60), with the multi-allelic variant rs144469431 removed. A subset

of n = 447 CGMS participants sequenced using 10X Genomics linked-read whole genome

sequencing technology (10XG, Supplementary Information), which facilitates improved phasing,

was used as the reference panel to phase these imputed data into haplotypes. We then

implemented two analyses. The first analysis used the same PLINK command as in (60) in an

unrelated set of CGMS Phe508del/Phe508del participants (n=1,164). The second analysis is in a

larger subset that includes related individuals and conducts haplotype association using linear

regression with a robust variance estimate that accounts for the relatedness (n=1,266), comparing

each of the eight haplotypes studied in (60) to a comparison group that includes all others using

an additive model.

RNA Sequencing, Quality Control and analysis

The CF human nasal epithelia (HNE) cells were sequenced on the Illumina HiSeq 2500 platform

(Illumina Inc. San Diego, California, USA) and aligned as described in (39). Expression counts

were quantified using RNA-SeQC (ver. 2.0.0) and normalized to transcripts per million (TPM)

(61) as well as trimmed mean of M values (TMM) measures (62) .

To compare the expression level for *SLC26A9* across the different airway models, we calculated

the TPM from naïve HNE for 82 CGMS participants and 6 healthy controls, 16 pairs of de-

identified cultured HNE and HBE, 17 pairs of de-identified naïve HNE and HBE and 9 CFIT

cultured HNE samples.

eQTLs were calculated from 79 CGMS participants for whom both genotype and RNA sequence

from naïve HNEs were available (Fig 1).   Quality control required TPM ≥ 0.1 and read counts $\geq$

6 in greater than 20% of the sample to be analyzed. FastQTL (ver. 2.0) was used to conduct

differential gene expression analysis of TMM-normalized read counts on SNP genotypes (63).

Covariates included the top 3 genotype principal components, 15 probabilistic estimation of

expression residual (PEER) factors, sample study source, sex, genotyping platform, RNA

integrity number (RIN) and PTPRC/CD45 gene expression which adjusts for immune cell

composition in the samples. The genotype principal components and PEER factors were

generated using R packages GENESIS (48, 49) and peer (64), respectively. The average

expression level of *SLC26A9* was compared across HBE and HNE in both cultured and naïve

paired tissues. Paired t-tests were conducted using the *t.test()* function in R v3.6.1 (65), based on

TPM.

For the Human Lung Atlas single cell data (40), cellular expression profiles were clustered by

nearest-neighbor for visualization. RNA count data and cell annotations provided in this dataset

were used; counts were normalized (library-size corrected) to 1,000,000 reads per cell and log-

scaled. Scanpy v1.8.2 in Python 3.7 was used for the *CFTR* and *SLC26A9* single-cell expression

visualization of the Human Lung Cell Atlas data (66).

A subset of these samples with expression from more than 500 genes and greater than 50,000

total mapped reads were used for statistical modeling of CFTR-SLC26A9 co-expression. Library

sizes were normalized using the TMM method. Log-transformed read counts per million (log-

CPMs) were generated using the normalized library sizes and were used to calculate the

Spearman's correlation between the *CFTR* and the *SLC26A9* genes. Expression raw read count

from *CFTR* was regressed on that of *SLC26A9* in the zero-inflated negative binomial model

analysis with a log link function. Normalized library size was adjusted using an offset term.

Zero-inflation was modelled by the detection rate variable which is the proportion of genes with

expression data in a cell. The effect size estimate indicates log-ratio relations between *CFTR* and

SLC26A9 expression. The Spearman's correlation and the zero-inflated negative binomial model

analysis were performed by R function cor.test() and package pscl (67), respectively.

Results

<u>*rs7512462 is associated with CF lung function in the absence of treatment measured as Saknorm*</u>

Using the International CF Gene Modifier consortium lung phenotype, Saknorm ((35);

Methods), we compared lung function across the three *CFTR* genotype groups. Saknorm

measures differ significantly between individuals with a gating variant (n=89) versus those who

are homozygous for Phe508del (n= 1,266; effect size=0.20, p=0.030), while individuals with two

MF variants (n=63) do not differ in Saknorm from Phe508del homozygotes (effect size= -0.11,

p=0.27).

In CGMS participants with at least one G551D variant (n=79), rs7512462 did not reach

statistical significance at the 0.05 level with Saknorm (effect size = 0.185, p=0.225). Meta-

combining the CGMS association evidence with association results from four independent

cohorts, a cohort from the French gene modifier study (FGS) with n=49 participants (32) and

three cohorts with n=272 participants reported in Eastman et al (43), results in an effect size of

0.11 with p=0. 05 and an effect size=0.12 with p=0.036 from inverse variance weighted and from

sample size weighted meta-analyses, respectively (Fig. S1; Supplementary Table 2). Meta-

analysis of rs7512462 Saknorm association from the FGS (32) and CGMS cohorts with at least

one gating variant approved for ivacaftor have similar but more variable effect size than that

from the G551D subset (effect size =0.12 with p=0.18; Supplementary Table 2).

In individuals from the CGMS who are homozygous Phe508del (n=1,266), each C allele is

associated with an increase in lung function, albeit with a smaller effect size (effect size = 0.069,

p=0.028, Fig. 2a; Fig. S2). Meta-analysis of this CGMS association with an rs7512462 Saknorm

association in n=1,802 individuals who are Phe508del/Phe508del from the FGS (32) also show

association in both inverse variance weighted (effect size=0.050, p=0.021) and sample size

weighted (effect size=0.046, p=0.037) meta-analyses (Fig. S2; Supplementary Table 2).

Constructing haplotypes in the CGMS in individuals homozygous for Phe508del as in (60) does

not provide evidence for significant low risk (LR) or high risk (HR) haplotypes contributing to

Saknorm variation (Supplementary Table 3) and does not provide greater power than using the

single SNP rs7512462 to mark the locus for association with lung function (Supplementary

Result; Supplementary Table 3).

Importantly, in individuals with two MF variants, the CC genotype is associated with improved

lung function when compared to individuals with the TT and TC genotype (effect size=0.45,

p=0.0083, Fig. 2a). This is consistent with the hypothesis that for rs7512462 marking SLC26A9

activity, SLC26A9 may be providing alternative chloride transport properties in individuals with

CFTR variants for whom no current approved therapies exist.

When combining CGMS participants from the three genotype groups in a joint multivariable

regression model to assess the association with rs7512462, the C allele is associated with greater

lung function (p=0.017 and 0.022 for additive and recessive models, respectively, Table 2).

Fitting an interaction term in this multivariable model, the C allele does not demonstrate a

statistically significant difference in effect size depending on one's *CFTR* genotype (interaction

p-values 0.90 and 0.46 for additive and recessive models, respectively).

463
Rs7512462 C allele is associated with improved response to CFTR modulators

Newly recruited participants into the CGMS on IVA (n=23) were, on average, older and had

worse baseline lung function than those included in (31) (Table 1). Despite the difference in

baseline characteristics and disease severity, we do observe additional supportive evidence for

improved lung function response when combining the newly and previously recruited

participants (difference in FEV_{1pp} pre and post treatment initiation) in individuals with the CC

genotype upon treatment with IVA (effect size=9.9, p=0.03, Table 3; Fig. 2b). Results from a

linear mixed-effect model which accounts for the longitudinal nature of the data provides

consistent results (effect size =12.76, p=0.025; Supplementary Table 4).

Through ongoing recruitment in the CGMS there were 104 participants prescribed LUM/IVA

clinically. In collaboration with the US PROSPECT observational study, we investigated lung

function response to LUM/IVA alone (n=91) and in a combined sample of n=195 individuals

homozygous for Phe508del stratified by rs7512462. Despite minimal clinical response to

LUM/IVA reported on average (14), we do observe a significant improvement in lung function

response in those with the CC genotype (p=0.002 in US PROSPECT and p= 0.006 for combined,

respectively; Table 3), akin to observations for IVA (Fig. 2b and (31)), and in studies of

improved CFTR function with the rs7512462 C allele in HNE (30) and HBE (18, 31) cells

obtained from individuals homozygous for Phe508del. Thus, the rs7512462 genotype shows

improved response to the LUM/IVA combination therapy in cohorts of CF patients who were

monitored observationally during their real-world experience with the approved modulators.

We investigated CFTR-mediated current in 36 cultured HNE from CGMS participants

homozygous for Phe508del upon treatment with VX-770+VX-809 (as in (30), corresponding to

the IVA/LUM combination; VX-770 applied acutely) and upon treatment with VX-770+VX-809

+ an amplifier under experimental investigation ((68); Fig. 3). We used the HNE from the

earliest passage available to us (P2) to align with (30). Defining the treatment response as the

difference in ΔI_{eq} -forskolin from DMSO to VX-770+ VX809 (n=36) or VX-770+ VX-809 +

amplifier (n=30), we see a significant improvement in CFTR function in the CC group (effect

size=-1.934, p=0.0022, Table 4) in HNE with VX-770+VX-809+ amplifier. The increase in

CFTR function in the CC group in the cultured HNE with VX-809 does not reach statistical

significance (effect size=-0.406, p=0.338, Table 4) unlike previous reports in HNE and in HBE

models, although the direction of effect is consistent. This difference in effect size made us

question the *SLC26A9* gene expression profile across different lung tissue models, especially

given the low passage of the primary HNE cultured cells studied by (30).

SLC26A9 expression differs across airway models

While investigating eQTLs in various airway tissue models, we observed that there is no

evidence supporting rs7512462 as an eQTL in the lungs from GTEx v8 (p=0.71) or from RNA

obtained from naïve HNE of individuals with CF (p=0.64, n=79) despite its association with

residual and activated current in Ussing chamber studies (30, 31). *SLC26A9* expression appears

generally low across several different lung model systems we investigated, with an average of

1.34 transcripts per million (TPM) (Fig. S3a). We generated a resource that contains the

transcriptomes from paired cultured and fresh naïve HNE and HBE tissue on the same

individuals (Methods; GEO ID: GSE172232)). Of the primary lung cell models we investigated,

the greatest expression is in the naïve HBE cells (TPM=1.94; Fig. S3a), and this expression level

is 2.1-fold greater than in the naïve HNE (p=0.04, paired analysis in n=17 HNE-HBE naïve

pairs). Unfortunately, naïve HBE cell models are not generally accessible for personalized

medicine approaches (39), and cultured models are the norm. Here cultured HBE show mean

expression with TPM=1.71 that is 2.5-fold greater than the CF cultured HNE (p=0.02, paired

analysis for n=16 HNE-HBE cultured pairs), although there is some indication that a reduction in

culturing time results in greater *SLC26A9* expression in the HNE (Fig. S3b).

Using single-cell RNA-seq data catalogued in the Human Lung Cell Atlas (40), we investigated

the expression of *SLC26A9* and *CFTR* across cell types. Within lung cells, both genes are

expressed in the epithelial cells of the alveoli and airway, particularly within alveolar type 2

(AT2) cells and club cells (Fig. 4). These cell types are also supported by single-cell Human

Protein Atlas data ((69); http://www.proteinatlas.org/), which reports expression in AT2 cells

(normalized TPM of 50.1 for *SLC26A9* and 65.6 for *CFTR*) and club cells (normalized TPM of

2.7 for *SLC26A9* and 17.8 for *CFTR*). Furthermore, single-cell GTEx data ((70, 71);

http://www.gtexportal.org/home) shows concordant evidence where, *SLC26A9* and *CFTR* reads

are observed in an appreciable fraction of AT2 cells (24.59% CFTR, 12.41% SLC26A9) and

club cells (28.79% *CFTR*, 5.45% *SLC26A9*).

We assessed the evidence for *CFTR-SLC26A9* co-expression among the club, basal and alveolar

epithelial cell types identified in the Human Lung Atlas study (40). Both the Spearman's

correlation and the zero-inflated negative binomial model indicated significant association

between the *CFTR* and the *SLC26A9* read counts for AT2 cells (Table 5). The model estimate

suggests positive co-expression between the two genes (log ratio = 0.00035, p=0.00974).

Phenome-wide Association Study (PheWAS) of rs7512462 and colocalization analysis

We used the GWAS ATLAS database (41) that includes 4,756 GWAS from 473 unique studies

with 3,302 unique traits, and the UK Biobank resource to investigate other non-CF traits

associated with rs7512462. The 10 traits with the smallest reported p-values are listed in Table 6,

four of which are respiratory phenotypes from the UK Biobank and Spirometa consortium (33):

PEF and FEV_1/FVC ratio. Saknorm, the lung function measurement used in the CF GWAS, is

also calculated from FEV_1 (5, 35). The list of significant phenotypes also includes our own CF

modifier gene study where we first identified rs7512462 as a modifier of intestinal obstruction at

birth, meconium ileus with evidence of an exocrine pancreatic origin ((1); Table 6).

Interestingly, an earlier age at menarche (which is associated with weight) and a higher male

waist circumference and waist-hip ratio are also associated with the rs7512462 C allele. The

association of rs7512462 with type 1 diabetes and the weight-related phenotypes suggest that the

role in these reproductive and metabolic phenotypes may likewise trace back to an exocrine

pancreatic origin. Significant colocalization analysis (column 'Colocalization P-value', Table 6)

calculated using the Simple Sum (1, 72) implemented in LocusFocus (59) between the

meconium ileus CF GWAS statistics (1) and the summary statistics from the PheWAS associated

traits supports that the same genetic variation contributes to the traits.

Airflow limitation is a key diagnostic feature of COPD (73). In the UK Biobank we analyzed

n=22,071 of 263,461 participants with moderate to severe airflow limitation defined by the

Global Initiative for Obstructive Lung Disease (GOLD) criteria (56). Although rs7512462 is a

modifier of PEF and FEV_1/FVC (p=2.74 $x10^{-44}$ and p=4.11$x10^{-5}$, respectively) from ((33); Table

6), the evidence is not as conclusive for FEV_1pp and COPD case control status in UK Biobank

(p=0.56, 0.0891, respectively; Fig. 5).

Discussion

The availability of CFTR modulators is altering care for many individuals with CF, although

variation in responses are apparent, partially due to individual genetic backgrounds. One such

genetic factor is *SLC26A9,* which contributes to early onset CF comorbidities in the pancreas and

intestine (1, 4, 22, 60). Unlike for these early-onset phenotypes where the rs71512462 SNP is a

SLC26A9 eQTL in the pancreas and SLC26A9 and CFTR appear to contribute to these

phenotypes independently (1, 7, 31), in the lungs the mechanism that is being marked by

rs7512462 is not immediately obvious from the genetic data. Meanwhile, some have also

questioned whether rs7512462 is even associated with lung function (43).

To address the connection between rs7512462 and SLC26A9, we integrate evidence from

population and functional studies. The rs7512462 SNP was shown to associate with lung

function or lung response to CFTR-modulators in individuals that carry *CFTR* variants that result

in apical membrane localization for CFTR (31) and this is further supported here. Although

rs7512462 does not show eQTL evidence based on lung tissue expression, SLC26A9 is present

in HBEs (28, 74, 75) and Fig. S3 and Larsen *et al* (28) show that SLC26A9 is a major

contributor to constitutive anion secretion across HBEs. In (31) Figure 3B prior to CFTR

correction in Phe508del/Phe508del HBE monolayers, rs7512462 shows evidence of association

with residual forskolin stimulated current ($P = 0.09$, -0.17 µA/cm^2 ΔI_{eq}-forskolin per C

protective allele) in Ussing chamber studies. A relation between rs7512462

genotype and transepithelial current in uncorrected Phe508del CFTR was also shown by others

in HNE cultures with Phe508del CFTR genotypes (30).

Experimental evidence for a relationship between the rs7512462 genotype and CFTR function in

airway cell models and here in CF participant responses was also observed by rescuing the

traffic-defective Phe508del with corrector modulators (30, 31). Published in vitro and cell studies

have demonstrated a CFTR-SLC26A9 interaction in lung cells and together with recent work by

((28, 74, 75) and references within), evidence is emerging that SLC26A9 may also stabilize

CFTR. Therefore, we interpret that the contribution of SLC26A9 that rs7512462 is marking for

lung phenotypes may be from both anion channel activity and enhancement of apical membrane

bound CFTR.

To address the uncertainty in evidence for *rs7512462* association with lung function (43), here

we extend several genetic association studies. We investigate the role of *rs7512462* genotype in

CF patients with different types of CFTR mutations and in treatment response to CFTR

modulators both in patient populations and in airway models. We align the findings and

previously published work with gene expression patterns including understanding of cell type

specific *SLC26A9* and *CFTR* co-expression, and now also consider the role of rs751242 in the

phenome and, in particular, in lung function measurements in non-CF populations. Significant

human genetic evidence that supports a role for *SLC26A9* in CF disease severity and CFTR

modulator response is accumulating. Here we provide the most comprehensive investigation of

the role of rs7512462 as a marker of *SLC26A9* activity in CF and non-CF populations.

The relationship between the *SLC26A9* rs7512462 marker and lung function in three types of

CFTR genotypes was revealing. Individuals with the CF-causing G551D gating variant show

association with rs7512462. Gating-deficient CFTR protein exhibits epithelial apical cell

membrane localization with reduced opening probability, resulting in reduced epithelial

chloride and bicarbonate secretion characteristic of CF (76). In contrast, individuals

homozygous for Phe508del, comprising the majority of CF cases, show more modest evidence of

association with rs7512462. Phe508del-CFTR is rapidly degraded intracellularly with minimal

surface membrane localization. Meanwhile, for the first time, we demonstrated that individuals

with MF variants do show rs7512462 association but with absence of CFTR protein cannot

respond to CFTR modulator therapy. The studies of MF alleles support that at least some aspect

of lung function contribution by SLC26A9 can be independent of CFTR. These investigations

align with several previous studies highlighting the potential for SLC26A9 to provide

(alternative) chloride transport that functions independently of CFTR (25, 26).

CF GWAS of early-onset CF pancreatic and intestinal phenotypes were CFTR genotype

independent (1-3, 7); that is, those homozygous for Phe508del still demonstrated genome-wide

significance with benefit from the C allele of rs7512462, a marker of *SLC26A9* gene expression

in CF phenotypes that show pre-natal onset (for example, meconium ileus). This may reflect that

SLC26A9 and CFTR may act independently at this stage of development and is consistent with

the observation that *Slc26a9* mRNA was high in the murine pancreas in the embryonic stages of

development when *Cftr* was low (31). Given the small sample size, the rs7512462 association

with lung function in individuals with two MF alleles requires further investigation and

independent replication. However, a consistent beneficial effect of the CC rs7512462 genotype

across several of our independent studies and disparate outcomes provides support that

modulation of SLC26A9 can provide alternative chloride transport and could be a therapeutic

target to improve lung function in individuals with any *CFTR* genotype. The modulation of

alternative channels, transporters and pumps to compensate for dysfunctional CFTR (19, 77),

and in particular SLC26A9 (9, 20, 31), would provide a mutation-agnostic approach and address

the current unmet need of the CF individuals with MF alleles.

Given other published reports assessing the rs7512462 relationship with lung function in

individuals with G551D variants (31, 32, 43), we used meta-analysis to summarize the current

state of evidence. Together, the weight of evidence supports a relationship between the *SLC26A9*

marker, rs7512462, and lung function in individuals with a G551D variant where there is cell-

surface localized CFTR protein, but reduced activity. In an expanded CGMS cohort, we also

replicated the enhancing effect of the rs7512462 C allele upon rescue of gating variants with

IVA, suggesting that the pre-treatment effect may be reflective of constitutive activity and/or

attributable to SLC26A9-aided residual CFTR function. Consistent with either is the suggestive

association we observed between rs7512462 and lung function prior to treatment with LUM/IVA

in individuals from the CGMS homozygous for Phe508del, with a reduced effect size possibly

reflective of reduced cell membrane localization and interaction.

LUM/IVA was the first approved modulator for those homozygous for Phe508del, on the basis

of reduced pulmonary exacerbations and lung function response. However, the average

improvement in lung function in clinical trials (14) and observational studies (34) has been

modest. To investigate whether the improvements in lung function from LUM/IVA are modified

by the *rs7512462* genotype, we also genotyped the DNA from participants of the US

observational LUM/IVA study, PROSPECT (https://clinicaltrials.gov/ct2/show/NCT02477319),

and demonstrated that although modest in its average improvement in lung function, those with

the CC rs7512462 genotype did exhibit the greatest benefit. Although this is the first report of

rs7512462 impact on clinical response, and in a real-world setting of treated patients, this finding

is consistent with published studies of CFTR function in primary HBE and HNE cells from

individuals homozygous for Phe508del by us (31) and others (30), respectively. Together these

findings across the two treated *CFTR* genotype groups replicate and expand previous reports (25,

26, 30, 31) that rs7512462 correlates with improved CFTR function.

We did evaluate CFTR function in nasal brushes from 36 individuals homozygous for Phe508del

in Ussing chamber studies following 24h exposure to vehicle (DMSO), VX-770 with corrector

VX-809 (corresponding to IVA/LUM) and a combination of VX-770, VX-809 and an

experimental amplifier (68). We observed a similar trend to that reported in (30) with VX-809,

although it did not reach statistical significance. When CFTR function was, however, augmented

with the amplifier, the difference in CFTR function pre- and post-treatment was greatest in the

cells with the rs7512462 CC genotype. These functional studies further support the hypothesis

that SLC26A9 will likely benefit any therapeutic situation with increased apical surface localized

CFTR protein, such as for the latest highly effective modulator treatment, ETI.

Although the population studies provide important insights into the relationship between CFTR

and SLC26A9 marked by rs7512462 *in vivo*, functional studies in cellular and animal models

will be necessary to understand the functional relationship between the two channels/transporters

(78) and how they may be working together. The expression studies presented here provide

guidance on the use of cellular models for SLC26A9 and further highlight potential limitations of

cultured HNE for the unique considerations of studying SLC26A9 and CFTR that are distinct

from the ones for studies of CFTR alone. Compared to naïve bronchial cells, we observed

greater variation and lower expression in naïve nasal cells. Furthermore, the duration of

culturing time of either HNE or HBE cells resulted in reduced *SLC26A9* expression. Presently,

the cultured HBE model appears superior to HNEs for investigations of SLC26A9, although

further investigation of culturing conditions and of cell differentiation should to be considered.

Interestingly, the most significant *SLC26A9* locus SNPs from the CF GWAS (1, 7) also associate

with lung function measurements in several large international studies: PEF and FEV_1/FVC

ratio in participants from the UK Biobank aged 40-69 (9, 33); PEF and FEV_1/FVC ratio in the

Spirometa consortium (33); and for the FEV_1/FVC ratio in 8-year-olds from the UK10K

consortium (79). These results align with our findings that, after correction of CF-causal CFTR

variants with modulators, *SLC26A9* locus SNPs are associated with improved lung function and

CFTR function.

It is noteworthy that decreased spirometry is diagnostic for other obstructive lung diseases such

as COPD (80). Several studies have reported similar pathobiology cascades between CF and

COPD due to dysfunctional CFTR and environmental risk factors for COPD (81-85). For

example, CFTR chloride channels show reduced capacity as a result of tobacco smoke and may

result in the mucus obstruction characteristic of COPD (84, 86) that is akin to that seen in CF. If

SLC26A9 augments chloride transport, SLC26A9 agonists could also be an effective therapeutic

strategy for COPD. In support of this premise is the association evidence provided here

demonstrating rs7512462 is a modifier of lung function in (33), with significant colocalization

evidence between the CF and their UK Biobank + Spirometa Consortium summary statistics at

the *SLC26A9* locus, reflective of a common underlying genetic contribution.

Conclusions

A role for SLC26A9 in the CF precision medicine landscape is an exciting prospect. SLC26A9

shows desirable characteristics (9) as an alternative therapeutic target for CF, including the

urgent need for options for CF individuals with MF alleles. The association between rs7512462

genotype and response to existing pharmaceuticals indicate the potential to refine personalized

combinations of modulators, and there is also support that SLC26A9 agonists may yield benefit

to any existing pharmacological or gene correction paradigm in CF, independent of *CFTR*

genotype. Further research should also address the potential for SLC26A9 agonists to improve

measures of lung function in non-CF populations.

List of abbreviations

CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane conductance regulator; IVA: Ivacaftor;

LUM: lumacaftor; TZE: tezacaftor; ETI: elexacaftor and tezacaftor combined with ivacaftor; US:

United States; GWAS: genome-wide association study; SLC26A9: Solute Carrier Family 26

member 9; GTEx: Genotype Tissue Expression project; eQTL: expression quantitative locus;

HBE: human bronchial epithelia; COPD: chronic obstructive pulmonary disease; CGMS:

Canadian CF Gene Modifier Study; HNE: human nasal epithelia; CFF: Cystic Fibrosis

Foundation; CCFRD: Canadian CF Patient Data Registry; FEV_1: forced expiratory volume in

one second; MF: minimal function; QC: quality control;FEV_{1pp}:forced expiratory volume in one

second percent predicted; TPM: transcripts per million; PheWAS: Phenome-wide Association

Study; PEF*:* peak expiratory flow; FVC: the forced vital capacity; FEV_1/FVC ratio: the ratio of

forced expiratory volume in one second to the forced vital capacity; CCFRD: Canadian CF

Patient Data Registry; Saknorm: the Survival adjusted average CF-specific Kulich

FEV_1 percentiles that is normalized; QC: quality control; CFIT: CF Canada Sick Kids Program

in CF Individualized Therapy; P2: culture at Passage 2; P3: culture at Passage 3; LR: low risk;

HR: high risk; PCs: principal components; TMM: trimmed mean of M values;

PEER: *probabilistic estimation of expression residual* ; RIN: RNA integrity number; ERS/ATS:

European Respiratory Society/American Thoracic Society.

Declarations

Ethics declarations

The Canadian Gene Modifier Study (CGMS) was approved by the Research Ethics Board of the

Hospital for Sick Children (# 0020020214 from 2012-2019 and #1000065760 from 2019-

present) and all participating sub-sites. Written informed consent was obtained from all

participants or parents/guardians/substitute decision makers prior to inclusion in the study. The

CGMS is approved by the Research Ethics Board of the Hospital for Sick Children for the usage

of public and external data. The US PROSPECT study provides data from a clinical trial

registered at clinicaltrial.gov, identifier NCT02477319, and we obtained these data through

application to the US CFF at https://www.cff.org/Research/Researcher-Resources/.

Consents for publication

Not applicable.

Data Availability

The datasets generated and/or analyzed in this paper are publicly available. Data from the

CGMS analyzed for the lung function pre- and post-modulator treatment are available from the

Canadian CF registry at https://www.cysticfibrosis.ca/our-programs/cf-registry/requesting-

canadian-cf-registry-data; the functional data and RNA-seq data from CGMS is available from

the CFIT program at https://lab.research.sickkids.ca/cfit/cystic-fibrosis-patients-families-

researchers/, and the paired cultured and fresh naïve HNE and HBE is available at GEO

(GSE172232). The US PROSPECT data were obtained through application to the US CFF at

https://www.cff.org/Research/Researcher-Resources/ and the study is registered

on https://clinicaltrials.gov/ct2/show/NCT02477319. The single-cell RNA-sequencing data are

downloaded from the Human Lung Cell Atlas at http://hlca.ds.czbiohug.org. The summary

statistics for the pheWAS study is available at https://atlas.ctglab.nl/PheWAS and the meconium

ileus association results that have been used for colocalization analysis can be downloaded at

https://lab.research.sickkids.ca/strug/publications-software/. The data used for the COPD

analysis are available through application to the UK Biobank.

Code availability

All code and analyses steps implemented to process the UK Biobank data are available at

https://github.com/strug-hub/UKBB_spirometry_on_COPD. The software used for

colocalization plotting and statistical testing is available at

https://locusfocus.research.sickkids.ca/. The other analyses did not require any custom codes and

are described in the Methods Section.

Competing interests

L.B. participated in a Vertex Virtual Advisory Board and she is a member of the CF Annual

Faculty, sponsored by Vertex Pharmaceuticals. D.M-C. received an honorarium for teaching

module development for Vertex Pharmaceuticals. N. M. is doing contract research trials for

Vertex Phaemaceuticals and Abbvie. A.L.S has received speaking fees for educational programs

sponsored by Vertex Pharmaceuticals. B.S.Q. has received speaker fees from Vertex

Pharmaceuticals and has served as site PI for several Vertex-sponsored clinical trials .W.M.L is a

study investigator for Vertex Pharmaceuticals. E.T., T.G. and F.R. act as a consultant for Vertex

Pharmaceuticals. M.S. participated in Vertex clinical trials and received payment for education

modules. J.G., G.H., C.W., C. Bartlett, N.P., S.M., F.L., K.K., J.A., A.H., M.S., M.E., G.C-M.,

D.A., S.B., C.Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., D.H., M.J.S., J.B., P.W., L.S.,

E.B., T.M., J.M.R and L.J.S. have no conflicts of interest.

Funding

Funding was provided by Cystic Fibrosis Foundation STRUG17PO, MORAES1610; Canadian Institutes of Health Research (FRN 167282), Cystic Fibrosis Canada (2626) and the CFIT Program funded by the SickKids Foundation and CF Canada; Natural Sciences and Engineering Research Council of Canada (RGPIN-2015- 03742, 250053-2013). This work was also funded by the Government of Canada through Genome Canada (OGI-148) and supported by a grant from the Government of Ontario. The funders of the study play no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author contributions:

L.J.S conceptualized the study and the design. C. Bartlett, F.L., K.K., J.A., A.H., M. Shaw, M.E., G.C-M., D.A., S.B., C. Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., L.B., D.M-C., D.H., M.J.S., N.M., J.B., E.T., A.L.S., B.S.Q., P.W., W.M.L., M. Solomon, E.B., T.J.M., T.G., F.R. enrolled the participants and collected the biospecimens. J.G., G.H., C.W., N.P., S.M., L.J.S. carried out the statistical and bioinformatic analyses, created the visualizations and constructed the tables and Figures. L.S., T.G, J.M.R and L.J.S provided important insights to interpret the results and clarify the technical details for the methods, J.G., G.H., C.W., N.P., J.M.R., L.J.S. wrote the paper and all authors edited the paper. All authors have read and approved the final manuscript.

Acknowledgments

We thank the US CF Foundation for the use of Part B of the PROSPECT observational study. We thank the Cystic Fibrosis Canada–SickKids Program for Individualized Therapy for access to

the RNA-sequencing of the nasal epithelia. We thank the patients, care providers and clinic

research assistants, collaborators, and principal investigators involved in CF Centers throughout

Canada for their contributions to the CF Canada Patient Registry and Canadian Gene Modifier

Study. Some of the research was conducted using the UK Biobank Resource under application

Number 40946. We thank Shaf Keshavjee for providing the bronchial cells for paired analysis of

gene expression and Hong Ouyang for culturing the epithelial cells. We thank Dr. John Miller

for providing the amplifier for the study. The authors wish to acknowledge the staff supporting

the High Performance Computing cluster and research helpdesk department and The Centre for

Applied Genomics at the Hospital for Sick Children, Toronto.

References

1. Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, et al. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genet. 2019;15(2):e1008007.

2. Miller MR, Soave D, Li W, Gong J, Pace RG, Boëlle PY, et al. Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. J Pediatr. 2015;166(5):1152-7 e6.

3. Soave D, Miller MR, Keenan K, Li W, Gong J, Ip W, et al. Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization study. Diabetes. 2014;63(6):2114-9.

4. Blackman S, Commander C, Watson C, Arcara K, Strug L, Stonebraker J, et al. Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. 2013;62:3627-35.

5. Corvol H, Blackman SM, Boëlle PY, Gallins PJ, Pace RG, Stonebraker JR, et al. Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun. 2015;6:8382.

6. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45-56.

7. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet. 2012;44(5):562-9.

8. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013;45(10):1160-7.

9. Strug LJ, Stephenson AL, Panjwani N, Harris A. Recent advances in developing therapeutics for cystic fibrosis. Hum Mol Genet. 2018;27(R2):R173-R86.

10. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-72.

11. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2(4):467-9.

12. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-8.

13. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-19.

14. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220-31.

15. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Jr., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237-45.

16. Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M. Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax. 2016;71(3):284-7.

17.   Martin SL, Saint-Criq V, Hwang TC, Csanady L. Ion channels as targets to treat cystic
fibrosis lung disease. J Cyst Fibros. 2018;17(2S):S22-S7.
18.   Balazs A, Mall MA. Role of the SLC26A9 Chloride Channel as Disease Modifier and
Potential Therapeutic Target in Cystic Fibrosis. Front Pharmacol. 2018;9:1112.
19.   Enterprise Therapeutics, editor Pharmacological characterisation of TMEM16A
regulators. The 13th European Cystic Fibrosis Basic Science Conference; 2016; Pisa, Italy.
20.   Mall MA, Galietta LJ. Targeting ion channels in cystic fibrosis. J Cyst Fibros.
2015;14(5):561-70.
21.   Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of
human genetic evidence for approved drug indications. Nature genetics. 2015;47(8):856-60.
22.   Aksit MA, Pace RG, Vecchio-Pagan B, Ling H, Rommens JM, Boelle PY, et al. Genetic
Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes
and Related Traits. J Clin Endocrinol Metab. 2020;105(5).
23.   Lin YC, Keenan K, Gong J, Panjwani N, Avolio J, Lin F, et al. Cystic fibrosis-related
diabetes onset can be predicted using biomarkers measured at birth. Genet Med. 2021;23(5):927-
33.
24.   Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across human
tissues. Science. 2020;369(6509):1318-30.
25.   Bertrand CA, Mitra S, Mishra SK, Wang X, Zhao Y, Pilewski JM, et al. The CFTR
trafficking mutation F508del inhibits the constitutive activity of SLC26A9. Am J Physiol Lung
Cell Mol Physiol. 2017;312(6):L912-L25.
26.   Bertrand CA, Zhang R, Pilewski JM, Frizzell RA. SLC26A9 is a constitutively active,
CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol.
2009;133(4):421-38.
27.   Salomon JJ, Spahn S, Wang X, Fullekrug J, Bertrand CA, Mall MA. Generation and
functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels.
Am J Physiol Lung Cell Mol Physiol. 2016:ajplung 00321 2015.
28.   Larsen MB, Choi JJ, Wang X, Myerburg MM, Frizzell RA, Bertrand CA. Separating the
contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
Am J Physiol Lung Cell Mol Physiol. 2021;321(6):L1147-L60.
29.   Liu X, Li T, Riederer B, Lenzen H, Ludolph L, Yeruva S, et al. Loss of Slc26a9 anion
transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-
deficient mice. Pflugers Arch. 2015;467(6):1261-75.
30.   Kmit A, Marson FAL, Pereira SV, Vinagre AM, Leite GS, Servidoni MF, et al. Extent of
rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells
correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1323-31.
31.   Strug LJ, Gonska T, He G, Keenan K, Ip W, Boelle PY, et al. Cystic fibrosis gene
modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum Mol Genet.
2016;25(20):4590-600.
32.   Corvol H, Mesinele J, Douksieh IH, Strug LJ, Boelle PY, Guillot L. SLC26A9 Gene Is
Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. Front
Pharmacol. 2018;9:828.
33.   Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al.
New genetic signals for lung function highlight pathways and chronic obstructive pulmonary
disease associations across multiple ancestries. Nature genetics. 2019;51(3):481-93.

34.   Sagel SD, Khan U, Heltshe SL, Clancy JP, Borowitz D, Gelfond D, et al. Clinical
Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-
CFTR. A Clinical Trial. Ann Am Thorac Soc. 2021;18(1):75-83.
35.   Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, et al. A novel lung
disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies.
Pediatr Pulmonol. 2011;46(9):857-69.
36.   Kim SO, Corey M, Stephenson AL, Strug LJ. Reference percentiles of FEV1 for the
Canadian cystic fibrosis population: comparisons across time and countries. Thorax.
2018;73(5):446-50.
37.   Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, et al. Disease-
specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit
Care Med. 2005;172(7):885-91.
38.   Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, et al. Modulators of
CFTR. Updates on clinical development and future directions. Eur J Med Chem.
2021;213:113195.
39.   Eckford PDW, McCormack J, Munsie L, He G, Stanojevic S, Pereira SL, et al. The CF
Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of
personalized medicine in CF. J Cyst Fibros. 2019;18(1):35-43.
40.   Travaglini KJ, Nabhan AN, Penland L, Sinha R, Gillich A, Sit RV, et al. A molecular cell
atlas of the human lung from single-cell RNA sequencing. Nature. 2020;587(7835):619-25.
41.   Watanabe K, Stringer S, Frei O, Umicevic Mirkov M, de Leeuw C, Polderman TJC, et al.
A global overview of pleiotropy and genetic architecture in complex traits. Nature genetics.
2019;51(9):1339-48.
42.   Harrell FEJ. Regression Modeling Strategies With Applications to Linear Models,
Logistic and Ordinal Regression, and Survival Analysis. Cham: Springer; 2015.
43.   Eastman AC, Pace RG, Dang H, Aksit MA, Vecchio-Pagan B, Lam AN, et al. SLC26A9
SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor
in cystic fibrosis patients with G551D-CFTR. J Cyst Fibros. 2021.
44.   Schwarzer G. metagen: Generic inverse variance meta-analysis. Preprint at https://cran.r-
project.org/web/packages/meta/meta.pdf. 2021.
45.   Viechtbauer W. metafor: Meta-Analysis Package for R. Preprint at https://cran.r-
project.org/web/packages/metafor/metafor.pdf. 2020.
46.   Gordon M, Lumley T. forestplot: Advanced Forest Plot Using 'grid' Graphics. Preprint at
https://cran.r-project.org/web/packages/forestplot/forestplot.pdf. 2021.
47.   Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models using
lme4. 2014.
48.   Conomos MP. Population Structure and Relatedness Inference using the GENESIS
Package 2021 [cited 2021 Feb-06].
49.   Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for
ancestry prediction and correction of stratification in the presence of relatedness. Genet
Epidemiol. 2015;39(4):276-93.
50.   Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust
relationship inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-73.
51.   Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet.
2006;2(12):e190.

52.   Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag;
2016.
53.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.
54.   Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open
access resource for identifying the causes of a wide range of complex diseases of middle and old
age. PLoS Med. 2015;12(3):e1001779.
55.   Band G, Marchini J. BGEN: a binary file format for imputed genotype and haplotype
data. bioRxiv2018.
56.   Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future
trends. Lancet. 2007;370(9589):765-73.
57.   Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank-
scale genotype datasets. Bioinformatics. 2017;33(17):2776-8.
58.   McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank-
based inverse normal transformation for quantitative trait analysis in genome-wide association
studies. Biometrics. 2020;76(4):1262-72.
59.   Panjwani N, Wang F, Mastromatteo S, Bao A, Wang C, He G, et al. LocusFocus: Web-
based colocalization for the annotation and functional follow-up of GWAS. PLoS Comput Biol.
2020;16(10):e1008336.
60.   Lam AN, Aksit MA, Vecchio-Pagan B, Shelton CA, Osorio DL, Anzmann AF, et al.
Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. J
Clin Invest. 2020;130(1):272-86.
61.   DeLuca DS, Levin JZ, Sivachenko A, Fennell T, Nazaire MD, Williams C, et al. RNA-
SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics.
2012;28(11):1530-2.
62.   Robinson MD, Oshlack A. A scaling normalization method for differential expression
analysis of RNA-seq data. Genome Biol. 2010;11(3):R25.
63.   Ongen H, Buil A, Brown AA, Dermitzakis ET, Delaneau O. Fast and efficient QTL
mapper for thousands of molecular phenotypes. Bioinformatics. 2016;32(10):1479-85.
64.   Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of
expression residuals (PEER) to obtain increased power and interpretability of gene expression
analyses. Nat Protoc. 2012;7(3):500-7.
65.   R Core Team. R: A language and environment for statistical computing. 2015.
66.   Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data
analysis. Genome Biol. 2018;19(1):15.
67.   Jackman S, Tahk A, Zeileis A, Maimone C, Fearon J, Meers Z. pscl: Political Science
Computational Laboratory. Preprint at https://cran.r-project.org/web/packages/pscl/pscl.pdf.
2020. 2020.
68.   Giuliano KA, Wachi S, Drew L, Dukovski D, Green O, Bastos C, et al. Use of a High-
Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological
Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors.
SLAS Discov. 2018;23(2):111-21.
69.   Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al.
Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.

70.   Eraslan G, Drokhlyansky E, Anand S, Subramanian A, Fiskin E, Slyper M, et al. Single-
nucleus cross-tissue molecular reference maps to decipher disease gene function. Preprint at
https://www.biorxiv.org/content/10.1101/2021.07.19.452954v1. 2021.
71.   GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
human tissues. Science. 2020;369(6509):1318-30.
72.   Wang F, Panjwani N, Wang C, Sun L, Strug LJ. A flexible summary-based colocalization
method with application to the mucin Cystic Fibrosis lung disease modifier locus. Accepted by.
AJHG. 2021.
73.   Stephens MB, Yew KS. Diagnosis of chronic obstructive pulmonary disease. Am Fam
Physician. 2008;78(1):87-92.
74.   Pinto MC, Quaresma MC, Silva IAL, Railean V, Ramalho SS, Amaral MD. Synergy in
Cystic Fibrosis Therapies: Targeting SLC26A9. Int J Mol Sci. 2021;22(23).
75.   Sato Y, Thomas DY, Hanrahan JW. The anion transporter SLC26A9 localizes to tight
junctions and is degraded by the proteasome when co-expressed with F508del-CFTR. J Biol
Chem. 2019;294(48):18269-84.
76.   Fischer H. The G551D CFTR chloride channel spurs the development of personalized
medicine. J Physiol. 2014;592(9):1907-8.
77.   Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nature
Reviews Disease Primers. 2015;1:1-19.
78.   Walter JD, Sawicka M, Dutzler R. Cryo-EM structures and functional characterization of
murine Slc26a9 reveal mechanism of uncoupled chloride transport. Elife. 2019;8.
79.   Baskurt Z, Mastromatteo S, Gong J, Wintle RF, Scherer SW, Strug LJ. VikNGS: a C++
variant integration kit for next generation sequencing association analysis. Bioinformatics.
2020;36(4):1283-5.
80.   Johns DP, Walters JA, Walters EH. Diagnosis and early detection of COPD using
spirometry. J Thorac Dis. 2014;6(11):1557-69.
81.   Cantin AM, Hanrahan JW, Bilodeau G, Ellis L, Dupuis A, Liao J, et al. Cystic fibrosis
transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir
Crit Care Med. 2006;173(10):1139-44.
82.   Clunes LA, Davies CM, Coakley RD, Aleksandrov AA, Henderson AG, Zeman KL, et
al. Cigarette smoke exposure induces CFTR internalization and insolubility, leading to airway
surface liquid dehydration. FASEB J. 2012;26(2):533-45.
83.   Raju SV, Jackson PL, Courville CA, McNicholas CM, Sloane PA, Sabbatini G, et al.
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance
regulator function. Am J Respir Crit Care Med. 2013;188(11):1321-30.
84.   Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, et al.
Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways
in COPD. Chest. 2013;144(2):498-506.
85.   Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, et al. A
pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator
dysfunction in smoking related lung disease. PLoS One. 2012;7(6):e39809.
86.   Mall MA. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary
Disease. Ann Am Thorac Soc. 2016;13 Suppl 2:S177-85.
1034

1035 **Figures**

1036

1037 **Fig.1.** Assessment of the association of rs7512462 in the Canadian CF Gene Modifier Study

1038 (CGMS) population broken down according to particular sub-study groups. Sample sizes

1039 indicated in parentheses represent the overlap with those published in (31). *This analysis is

1040 combined with the US PROSPECT cohort.

1041

1042

Fig. 2. Participant lung function or lung treatment response categorized by rs7512462 genotype.

(a) Boxplots of lung function from CGMS participants prior to modulator treatment, measured as

Saknorm across different CFTR mutation groups. Saknorm is calculated as in (5, 35) with FEV_1

measurements taken prior to modulator treatment, if applicable. (b) Boxplot includes an overlay

with a stripchart for treatment response in patients on IVA (n=45), LUM/IVA in PROSPECT

cohort (n=91) or LUM/IVA in combined PROSPECT and CGMS samples (n=195). The center

line, upper and lower box limits of boxplots correspond to the median, the third quartile (Q3) and

the first quartiles (Q1), respectively; whiskers reflect the 1.5x interquartile range (IQR), i.e.

bottom whisker is Q1-1.5xIQR and upper whisker is Q3 +1.5 x IQR). Each dot represents an

individual measurement. Following (31), the treatment response for IVA is defined as the

difference between the mean post-treatment FEV_{1pp} within 15 to 400 days and FEV_{1pp} baseline.

1054   Response for LUM/IVA is defined as the difference in FEV_{1pp} between the first post treatment

1055   within 5 to 7 months to the baseline ((38); Methods).

1056

1057

1058

Fig.3. Boxplot overlayed with stripchart for CFTR function by rs7512462 genotype in HNE

cultured to P2. The center line, upper and lower box limits of boxplots correspond to the median,

the third quartile (Q3) and the first quartiles (Q1), respectively; whiskers reflect the 1.5x

interquartile range (IQR), i.e. bottom whisker is Q1-1.5xIQR and upper whisker is Q3 +1.5 x

IQR). Each dot represents an individual measurement. The CFTR function is defined as the

difference in ΔIeq-forskolin from treatment with VX-770+VX-809 (left; n=36) or VX-770+VX-

809+amplifier (right; n=30) to DMSO vehicle in CFTR-mediated current in cultured HNE from

participants homozygous for Phe508del. More negative measurements reflect greater CFTR

function.

1068

Fig. 4. CFTR and SLC26A9 single-cell expression from the Human Lung Cell Atlas (40).

(a) Lung cell expression profiles from three individuals were clustered by nearest-neighbor and

visualized using uniform manifold approximation and projection (UMAP). Normalized and log-

scaled RNA counts for CFTR and SLC26A9 are plotted for each cell. Tissue compartment as

defined by the Human Lung Cell Atlas is shown; expression of both CTFR and SLC26A9 is

primarily restricted to epithelial cells; (b) UMAP clustering of epithelial lung cells only, cell

types were annotated in the Human Lung Cell Atlas and (c) Breakdown of CFTR and SLC26A9

expression by cell type. Cells were grouped as having CFTR read count > 1 (red), SLC26A9 > 1

(blue) or co-expressing both (purple). Cell total varies and is annotated for each cell type.

1078

Fig. 5. Lung function measures colocalize with CF meconium ileus GWAS at the *SLC26A9*

locus. Visualization of colocalization using LocusFocus (59). Peak expiratory flow (PEF)

association (n=345,265) from (33) is shown as circles with corresponding left y-axis against

lines that trace (1) GTEx v7 adult lung eQTLs for *SLC26A9*; (2) meconium ileus GWAS (1); (3)

FEV_{1pp} in UKBB participants (N=263,461; 22,071 of which have COPD as per GOLD level 2-4

definitions); (4) FEV1/FVC ratio from (33) (highest effective sample size is 396,686, a function

of sample size (N=400,102) times imputation quality); and (5) Chronic obstructive pulmonary

disease (COPD) case-control (22,071 cases and 241,390 controls). The choice of y-axis scales

and primary dataset is for visualization purposes only and does not influence colocalization test

result conclusions. There is a known gap on the human reference GRCh37 at chr1:205,922,708-

206,072,707, which corresponds to the white gap in the figure as no variants exist. Lines traverse

the lowest p-values per window as a visual guide (window size=6.67Kbp) with corresponding

right y-axis. A total of 85 SNPs in this region were used to test for colocalization using the

Simple Sum method (1, 72). The Simple Sum colocalization test is implemented in the grey

region, which was selected to match the observed peak at chr1:205,899,000-205,925,000. The

color of the circles reflects the pairwise linkage disequilibrium (LD) with the rs7512462 lead

SNP (purple) using the European subset of the 1000 Genomes Project, with varying strength of

LD depicted with a different colour as denoted in the legend.

1097

1098

 Tables

1100 **Table 1.** Characteristics of participants included for response to CFTR modulators from the

1101 CGMS and US PROSPECT studies. The lung function measure used for the CFTR modulator

1102 study is forced expiratory volume in one second percent predicted (FEV_{1pp}). A subset of n=22

1103 individuals from CGMS on IVA were included for analysis in (31) while n=23 are newly-

1104 recruited into the CGMS.

Participants on CFTR modulator	Participant Characteristics	CGMS Participants in CFTR modulator study			US PROSPECT
		CGMS IVA (In (31), n=22[*])	CGMS IVA (new, n=23)	CGMS LUM/IVA (n=104)	LUM/IVA (n=91)
rs7512462	TT/TC/CC	11/10/1	12/9/2	41/48/15	30/50/11
age	mean (range)	26.49 (6.1-58.3)	31.3 (14.0-55.3)	25.7 (10.5-55)	20.9 (6-57)
	age <= 12	5	0	2	23
	age (12,20]	4	3	38	27
	age (20,30]	3	11	38	24
	age>30	10	9	26	17
sex	female (%)	16 (72.7%)	13 (56.3%)	56 (53.8%)	52 (57.1%)
FEV_{1pp} baseline	mean (range)	66.6 (30.7-90.4)	58.9 (30.9-89.6)	59.6 (30.8-95.5)	75.7 (31.7-95.8)
Number of post-treatment FEV_{1pp} in 400 days	median (range)	4 (1-6)	4 (1-20)	6 (1-33)	4 (2-4)

1105
1106 [*]one sample with FEV_{1pp} baseline outside the inclusion criteria and another who received a lung
1107 transplant were removed.
1108

1109

1110 **Table 2.** Association between Saknorm and rs7512462 using additive and recessive codings in

1111 the CGMS cohort including individuals with a gating variant, individuals who are homozygous

1112 Phe508del or those who carry two MF alleles.

Models	Covariate	Effect size	S.E.	P-value
Additive	rs7512462_C	0.072	0.030	0.017
	CFTR-Gating/Other	0.210	0.094	0.025
	CFTR-MF/MF	-0.099	0.099	0.317
	Saknorm new reference equation	-0.244	0.050	1.41×10^{-6}
Recessive	rs7512462_CC	0.130	0.057	0.022
	CFTR-Gating/Other	0.208	0.093	0.026
	CFTR-MF/MF	-0.101	0.099	0.307
	Saknorm new reference equation	-0.244	0.050	1.32×10^{-6}

Saknorm is a continuous FEV_1- based CF-specific percentile that is normalized and accounts for
age, sex and height and is survival adjusted (35). Saknorm is calculated as in (5, 37) with
FEV_1 measurements taken prior to modulator treatment, if applicable. The combined samples
include individuals with gating mutations (n=89), individuals homozygous for Phe508del
(n=1,266) or those with two minimal function (MF) mutations (n=63). All analyses use the
robust covariance matrix estimates by the R package 'rms' (42). In addition to rs7512462, both
models include a *CFTR* mutation group indicator, with reference group as homozygous
Phe508del. Saknorm new reference equation is an indicator for the reference equation used to
calculate Saknorm (Methods) depending on the year the lung function measurement was taken.
1122

1123

1124   **Table 3.** Association of rs7512462 for CFTR modulator response.

Studies	Covariates	Effect Size	S.E.	P-value
IVA(CGMS)	Age at baseline	-0.077	0.095	0.419
	FEV1pp at baseline	-0.025	0.073	0.731
	rs7512462_CC	9.905	4.477	0.033
	Early CGMS Cohort	5.336	2.606	0.047
LUM/IVA (US PROSPECT)	Age at baseline	-0.188	0.074	0.014
	FEV1pp at baseline	-0.123	0.053	0.024
	rs7512462_CC	8.518	2.657	0.002
LUM/IVA (US PROSPECT+CGMS)	Age at baseline	-0.119	0.064	0.066
	FEV1pp at baseline	-0.069	0.037	0.066
	rs7512462_CC	5.217	1.871	0.006
	PROSPECT Cohort	0.865	1.401	0.540

CFTR modulator response is the difference between the FEV_{1pp} after the modulator response and
the value at last visit before the treatment initiation within 3 months as defined in Methods.
Increased ΔFEV_{1pp} indicates better treatment response. Sample sizes in each CFTR modulator
treatment group are n=45 for IVA (CGMS), n=91 for LUM/IVA (US PROSPECT) and n=195
for the combined LUM/IVA analysis of the US PROSPECT and CGMS participants (US
PROSPECT+CGMS). Early CGMS Cohort for IVA-CGMS reflects an indicator for those
participants that were included in an earlier published study (31). LUM/IVA studies were also
adjusted for population structure by PCs (n=7 PCs for US PROSPECT and n=4 for US
PROSPECT+CGMS).   PROSPECT Cohort is an indicator of whether the individual was a
participant in the US PROSPECT study or the CGMS. All results use robust variance estimates.
1135
1136

1137

1138   Table 4. Association of rs7512462 for change of function to modulator treatment.

Studies	Covariates	Effect Size	S.E.	P-value
CFTR-mediated current (VX-770+VX-809)	rs7512462_CC	-0.406	0.417	0.3375
	Standard media	-1.969	0.456	0.0001
CFTR-mediated current (VX-770+VX-809+ amplifier)	rs7512462_CC	-1.934	0.572	0.0022
	Standard media	-2.170	0.697	0.0044

1139
Forskolin-stimulated currents mediated by CFTR (measured as change in current after
application of forskolin, ΔI_{eq}-forskolin) is used as the treatment response; more negative values
correspond to more CFTR activity. Functional study includes HNEs from individuals
homozygous for Phe508del with VX-770+VX-809 (n=36) and VX-770+VX-809+ amplifier
(n=30; a subset of the 36 samples tested with 770+VX-809) measured as difference in CFTR-
mediated current after applying forskolin regressed on rs7512462 with a recessive coding. All
results use robust variance estimates.
1147

1148

1149

1150

1151

1152

1153

1154

1155 Table 5: Co-expression between *SLC26A9* and *CFTR* using the Human Lung Atlas data (40).

Cell Type	Number of Cells	Zero-Inflated Negative Binomial Model			Spearman's Correlation	
		Effect Size	S.E.	P-Value	Rho	P-Value
Club	895	-0.00007	0.00125	0.9564	0.05173	0.12196
AT2[*]	760	0.00035	0.00013	0.0097	0.13215	0.00026
Basal	240	-11.65287	94.65422	0.9020	-0.02365	0.71544
AT1[*]	421	-8.41119	152.8630	0.9561	-0.01178	0.80962
AT2-s[*]	201	0.00143	0.00122	0.2433	0.28686	0.00004
Differentiating Basal	43	-0.02385	0.01931	0.2168	0.07235	0.64478
AT2 and AT2-s	961	0.00041	0.00014	0.0036	0.16567	< 0.00001
AT1, AT2 and AT2-s	1382	0.00048	0.00015	0.0018	0.32261	< 0.00001

The effect size estimate from zero-inflated negative binomial model indicates log-ratio relations
between *CFTR* and *SLC26A9* expression. Values greater than zero correspond to positive co-
expression. Spearman's correlation estimates (rho) were calculated using log-transformed read
counts per million measures for *CFTR* and *SLC26A9*. The Spearman's correlation and the zero-
inflated negative binomial model analysis were performed by R function cor.test() and package
pscl (67), respectively. All p-values indicate two-sided statistical test results.
[*]: AT2: Alveolar Epithelial Type 2; AT1: Alveolar Epithelial Type 1; AT2-s: Signaling Alveolar
Epithelial Type 2
1164

1165

1166

1167 **Table 6.** The 10 phenotypes with smallest rs7512462 association p-value obtained from the

1168 GWAS ATLAS (41).

PMID	Domain	Trait	Effect Size	P-value at rs7512462	N	Colocalization P-value
30804560	Respiratory	PEF (UKBB)	0.038	4.33×10^{46}	321,047	$2.24. \times 10^{-9}$
30804560	Respiratory	PEF (Meta of UKBB and Spirometa)	0.037	2.74×10^{-44}	345,265	2.82×10^{-8}
30807572	Gastrointestinal	Meconium ileus in CF	-0.289	1.86×10^{-9}	6,770	NA
28436984	Reproduction	Age at menarche	-0.021	3.93×10^{-6}	252,514	3.63×10^{-8}
30804560	Respiratory	FEV_1/FVC ratio (Meta of UKBB and Spirometa)	0.01	4.11×10^{-5}	400,102	6.03×10^{-9}
30804560	Respiratory	FEV_1/FVC ratio (UKBB)	0.01	1.44×10^{-4}	321,047	2.24×10^{-8}
23754948	Metabolic	Waist circumference (male)	0.03	2.2×10^{-4}	36,231	7.08×10^{-9}
25231870	Reproduction	Age at menarche	-0.023	3.2×10^{-4}	132,989	7.41×10^{-9}
19430480	Endocrine	Type 1 Diabetes	NA	7.47×10^{-4}	7,982	NA
23754948	Metabolic	Waist-hip ratio (male)	0.028	7.7×10^{-4}	34,629	1.78×10^{-8}

The colocalization p-value assesses evidence for common genetic contributions between the
corresponding study phenotype and the meconium ileus CF GWAS (1) at chr1:205,895,000-
205,921,000 locus. The effect allele in all studies is C, and the other allele is T, except for type 1
diabetes, where the effect size is not reported for the SNP in the original summary statistics from
the listed publication (PMID). PheWAS significance level is $p<1.05 \times 10^{-5}$ after adjusting for
4,756 GWAS in the database (alpha 0.05). UKBB refers to an analysis using the UK Biobank.
'Colocalization P-value' represents the p-values from the colocalization analysis calculated here
with the CF GWAS summary statistics in (1) for the corresponding phenotype, using
LocusFocus (59) calculated on the chr1: 205,895,000-205,925,000 region in hg19. *NA* in this
column reflects a lack of information available to carry out the colocalization analysis.
1179

Information about Supplementary Material

File name: Supplementary File_clean

File format: docx

Title of the data: Supplementary Information; Supplementary Result; Supplementary Figures and Supplementary Tables.

Description of the Data: This file includes the supplementary materials for the paper '**Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease**'

Supplementary Information includes the following subsections:

Sample Genotyping and Quality Control; *High molecular weight DNA extraction methods; Library preparation and 10x Genomics sequencing reads processing;* Phasing *imputed* genotype data using *the* 10XG *multi-sample VCF* file as the reference*; HBE and HNE sampling*;

Cell Culturing; Ussing chamber studies with primary human nasal epithelial cells; and *PheWAS data extraction and Colocalization with CF GWAS Summary Statistics.*

Supplementary Result includes:

Haplotype association with Saknorm in CGMS participants homozygous for Phe508del

There are three figures in section **Supplementary Figures:**

Fig. S1. Forest plot of association between rs7512462 and lung function, measured as Saknorm (9) in individuals with at least one G551D variant.

Fig. S2. Forest plot of association between rs7512462 and lung function, measured as Saknorm (9) in individuals homozygous for Phe508del.

1202   **Fig. S3**. SLC26A9 gene expression in various tissue models to guide functional studies.

1203

There are four tables in section **Supplementary Tables**:

Supplementary Table 1: Number of participants removed according to the exclusion criteria for

the CFTR modulator study.

Supplementary Table 2: Meta-analysis for the association between rs7512462 and lung

function prior to treatment with Ivacaftor.

Supplementary Table 3: Haplotype association with Saknorm in individuals in the CGMS who

are homozygous Phe508del.

Supplementary Table 4: Association analysis using a linear mixed model with a random

intercept with n=45 individuals on ivacaftor with multiple follow-up measures within [15,400]

days.

1214